Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2017-08-04 Director's Dealing
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2017-08-04 English
PRIMARY DOCUMENT
Director's Dealing
2017-08-04 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans and employee stock purchase plans. The text includes details about the registration of additional shares under the Amended and Restated 2014 Stock Incentive Plan and the 2015 Employee Stock Purchase Plan. It contains legal and regulatory language typical of registration statements, including calculation of registration fees, signatures, and exhibits. This is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-06-15 English
PRIMARY DOCUMENT
Director's Dealing
2017-06-02 English
PRIMARY DOCUMENT
Director's Dealing
2017-06-02 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 31, 2017. It announces the appointment of a new Chief Operating Officer and the departure of an Executive Vice President and Chief Commercial Officer. It also includes the submission of matters to a vote of security holders at the 2017 Annual Meeting, with detailed voting results for director elections and ratification of the independent auditor. The content focuses on management changes and voting results from the annual meeting. There are no financial statements or detailed financial performance data included. The document is not an annual report, earnings release, or interim report. The primary content is about changes in senior management and voting results. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG), and official results from shareholder votes at any general meeting fall under Declaration of Voting Results & Voting Rights Announcements (DVA). Since both types of information are present, but the voting results are detailed and official, the document fits best under Declaration of Voting Results & Voting Rights Announcements (DVA). The length of the document (over 10,000 characters) and the detailed voting results support this classification rather than a brief announcement. Therefore, the filing type code is DVA with high confidence.
2017-05-31 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.